⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 3, 2024Open Access

Figure S15 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways

Signe K. Skadborg Simone Maarup Arianna Draghi Annie Borch Sille Hendriksen Filip Mundt Vilde Pedersen Matthias Mann Ib Jarle Christensen Jane Skjøth-Ramussen Christina W. Yde Bjarne Winther Kristensen Hans Skovgaard Poulsen Benedikte Hasselbalch Inge Marie Svane Ulrik Lassen Sine Reker Hadrup

View Full Paper

Ask AI

Bookmark

Share

Abstract

Proteomics comparison of samples from patients with tumor reactive and non-reactive TILs in the Nivolumab treated patient group.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Skadborg et al. (2024) studied this question.

synapsesocial.com/papers/68e598e8b6db643587533aad https://doi.org/10.1158/2326-6066.26926036

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S13 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
2Figure S8 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
3Figure S10 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
4Figure S6 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
5Figure S11 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024